palovarotene palovarotene palovarotene, sold under the brand name sohonos, is a medication used for the treatment of heterotopic ossification (ho) and fibrodysplasia ossificans progressiva (fop). it is a highly selective retinoic acid receptor gamma (rarγ) agonist. palovaroteneclinical datatrade namessohonosroutes ofadministrationby mouthatc codem09ax11 (who) legal statuslegal status ca: ℞-only identifiers iupac name 4-ethenyl]benzoic acid cas number410528-02-8 ypubchem cid10295295chemspider8470763unii28k6i5m16gchemical and physical dataformulac27h30n2o2molar mass414.549 g·mol−13d model (jsmol)interactive image smiles cc1(ccc(c2=c1c=c(c(=c2)/c=c/c3=cc=c(c=c3)c(=o)o)cn4c=cc=n4)(c)c)c inchi inchi=1s/c27h30n2o2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17h,12-13,18h2,1-4h3,(h,30,31)/b11-8+key:ytfhcxipdihoia-dhzhzojosa-n palovarotene is being developed by ipsen biopharmaceuticals and was granted priority review and orphan drug designations by the united states food and drug administration (fda) for the treatment of fibrodysplasia ossificans progressiva and orphan medicinal product designation by the european medicines agency (ema) in 2014. phase ii clinical studies failed to show a significant change in heterotopic bone volume, the main outcome measure, but prompted further investigation in a phase iii clinical trial. in december 2022, the fda declined to approve palovarotene for the fibrodysplasia ossificans progressive without additional clinical trial data. in january 2023, the european medicines agency (ema) recommended the refusal of the marketing authorization for sohonos for the treatment of fibrodysplasia ossificans progressiva. history palovarotene is a retinoic acid receptor gamma (rarγ) agonist licensed to clementia pharmaceuticals from roche pharmaceuticals. at roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (copd). a one-year trial did not demonstrate a significant benefit on lung density in moderate-to-severe emphysema secondary to severe α(1)-antitrypsin deficiency. in 2011, animal studies demonstrated that rarγ agonists, including palovarotene, blocked new bone formation in both an injury-induced mouse model of heterotopic ossification (ho) and a genetically modified biological mouse model of fibrodysplasia ossificans progressiva containing a continuously active acvr1/alk2 receptor in a dose-dependent manner. a 2016 study demonstrated that palovarotene also inhibited spontaneous heterotopic ossification, maintained limb mobility and functioning, and restored skeletal growth in fibrodysplasia ossificans progressiva mouse models. research phase ii clementia submitted a new drug application for palovarotene for the treatment of fibrodysplasia ossificans progressiva after observing positive phase ii results. phase iii in december 2019, ipsen issued a partial clinical hold for people under the age of 14, due to reports of early fusion of growth plates. ipsen acquired clementia in 2019.